news
FDA approves Vimpat for partial-onset seizures in paediatric epilepsy
FDA approves Vimpat for partial-onset seizures in paediatric epilepsy patients as an oral solution or a convenient tablet...
List view / Grid view
Epilepsy
news
UCB receives EU approval for paediatric anti-epileptic drug
UCB has announced that the EC has approved the use of its anti-epileptic drug Vimpatas in the treatment of partial-onset seizures...
news
CBD may protect against psychiatric risk from high-THC cannabis strains
Neuroscientists have found that cannabidiol reduces symptoms such as impaired memory in adolescent mice simultaneously exposed to THC...
news
Latency of seizures determined by diet
Researchers have connected docosahexaenoic (DHA) synthesis to oestrogen production and consequentially brain health...
news
Compound derived from marijuana interacts with antiepileptic drugs
Cannabidiol is being studied as a potential anticonvulsant, and it has demonstrated effectiveness in animal models of epilepsy and in humans...
news
Study finds genetic basis for drug response in childhood absence epilepsy
13 April 2017 | By Niamh Marriott, Junior Editor
A new childhood absence epilepsy study has identified genes that show individual reactions and could be used as a precision medicine approach...
news
High efficacy & 0 adverse effects in hemp oil study to treat epileptic children
22 March 2017 | By Niamh Marriott, Junior Editor
HempMeds Mexico has revealed the positive results of a recent cannabis study conducted on the effects of the Real Scientific Hemp Oil-X...
article
E is for Epilepsy
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
E is for Epilepsy - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research on Epilepsy...
news
Martindale’s epilepsy oral suspension product approved in 7 European countries
27 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Clobazam oral suspension is used principally as an adjunctive therapy for epilepsy with the formulation particularly suitable for children and young adults...
news
Infantile spasms selected as 4th target indication for Epidiolex
21 June 2016 | By Victoria White, Digital Content Producer
GW Pharmaceuticals has selected infantile spasms as the fourth target indication for its Epidiolex orphan paediatric epilepsy development programme...
news
Aprecia’s 3D-printed Spritam now available in the US
24 March 2016 | By Victoria White
Aprecia’s Spritam (levetiracetam) tablets, for oral suspension, are now available in the US as an adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures.
news
GW announces positive results for Epidiolex in Dravet syndrome
14 March 2016 | By Victoria White
Epidiolex achieved the primary endpoint of a significant reduction in convulsive seizures assessed over the entire treatment period compared with placebo...
news
Brivaracetam launches in the UK as a new option for patients with uncontrolled epilepsy
29 February 2016 | By Victoria White
UCB’s Briviact (brivaracetam) has been authorised in the UK as an add-on treatment for partial onset seizures with or without secondary generalised seizures...
news
Eisai presents new data for perampanel at AES 2015
8 December 2015 | By Victoria White
New data, presented at AES 2015, show that Eisai's Fycompa (perampanel) treatment reduces primary and secondary generalised tonic clonic seizures and is well tolerated versus placebo...
news
Real world data for eslicarbazepine acetate presented at AES
7 December 2015 | By Victoria White
The data shows that a good proportion of people with partial-onset seizures, who have not responded when treated with carbamazepine, may respond to eslicarbazepine acetate...
